Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease
Under the terms of the collaboration, Santhera will conduct all clinical development for regulatory approval in Europe and in the US. Takeda will support the development work and will obtain an exclusive license to market Idebenone (SNT-MC17) in the European Union and Switzerland. Santhera will in return receive an upfront payment of Euro 5 million, development milestones and royalties from Takeda. Full financial terms were not disclosed. Santhera will supply drug product to Takeda for Europe. In the US, Santhera plans to market Idebenone (SNT-MC17) on its own.
FRDA is a hereditary and disabling neuromuscular disorder that severely impacts quality of life and reduces patients' life expectancies substantially. Although FRDA is primarily a neurological disease, cardiac symptoms are well recognized to be a life-threatening complication of the disease. The most common cardiac manifestation is hypertrophic cardiomyopathy which ultimately causes death in the majority of FRDA patients.
It has been shown that Idebenone (SNT-MC17), a small molecule oral therapy, can improve mitochondrial function and/or reduce oxidative stress in muscle cells, heart cells and neurons. By protecting heart muscle cells form the oxidative stress that is mainly responsible for the deterioration of the heart muscle in FRDA, Idebenone (SNT-MC17) could offer the first therapy option which can prolong the lives of patients.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.